whitepaper
Whitepaper: Serum-free and Animal-free Research
Discover how the adoption of animal-free media/supplements can improve reproducibility in cell culture and biotherapeutic research.
List view / Grid view
Immunotherapy
whitepaper
Whitepaper: PSMA Protein in the Battle Against Cancer
The PSMA Protein is a new therapeutic hot target. In this article, learn about its growing role in the fight against prostate cancer and beyond.
news
Researchers have created a new view of how B cells recognise threats such as viruses
The researchers say their new discovery could be used to design better vaccines and to gain a deeper insight into autoimmune diseases and allergies.
news
Stopping immune cell leakage from tumours could improve skin cancer treatment
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
news
New immunotherapy approach holds promise for ovarian cancer
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
article
Transforming the way cancer vaccines are designed and made
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
news
The role immunological memory plays in fighting disease
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
article
Developing state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
article
Allogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
news
Major lung cancer mechanism can be used to evade immune attack
US researchers found high levels of XBP1s in lung cancer cells, which plays a key part in regulating the local immune environment in lung tumours, and can be disabled to increase anti-cancer immunity
news
Scientists identify a biomarker that predicts CAR T-cell therapy efficacy
Combining AI with cutting-edge flow cytometry and massive sequencing technologies, researchers describe CAR T cell characteristics that determine their therapeutic capacity for the first time.
news
Life-saving approach may overcome persistent obstacles to cell transplantation and immunotherapy
In their study, researchers duped antibodies with a decoy to prevent rejection of transplanted cells.
article
When exhausted, cancer-fighting T cells may switch sides
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
